Evidence Level
Red Yeast Rice is a natural supplement that has been extensively studied for its lipid-lowering effects. The CCSPS trial by Lu et al. (2008) remains the largest cardiovascular outcomes study of any supplement, demonstrating significant reductions in cardiac events and mortality. A meta-analysis by Li et al. (2014) confirmed LDL-C reductions of 1.02 mmol/L across 13 randomized controlled trials. Becker et al. (2009) further highlighted its efficacy in statin-intolerant patients.
Recent studies reinforce these findings. Trogkanis et al. (2024) conducted a systematic review and meta-analysis of 14 double-blind clinical trials, showing significant reductions in total cholesterol (-37.43 mg/dL, p<0.05) and LDL-C (-35.82 mg/dL, p<0.05). Rahmani et al. (2023) analyzed 24 randomized-controlled trials involving 3623 participants, indicating that Red Yeast Rice lowers total cholesterol, LDL-C, triglycerides, and raises HDL-C.
Safety is a critical consideration. Fogacci et al. (2019) reviewed 53 RCTs with 8535 participants, concluding that Red Yeast Rice supplementation is safe. However, variability among products persists, with some containing citrinin, a nephrotoxic contaminant. Standardized, third-party tested products are essential to ensure efficacy and safety.
Xuezhikang has been identified as particularly effective for reducing total and LDL cholesterol in hyperlipidaemia patients (Xu et al., 2022). Overall, Red Yeast Rice is a valuable option for managing dyslipidemia, supported by evidence across various populations.